Skip to content

Search

Showing results for "lung disease preterm"

Frequently asked questions

Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).

Maddie

Maddie Age 20. Trial participant, project community member, volunteer. Without input from the community, we can't see how our research is impacting

Who gets asthma, and why?

Citation: Evans DJ, D Sly PD, Foster P, Donovan C. Who gets asthma, and why? Med J Aust. 2025;223(S10):S19-S23. Keywords: Asthma; Lung diseases;

Healthy Ears Clinical Trial: A telehealth-facilitated randomised-controlled trial utilising a health promotion intervention to resolve otitis media with effusion for children won specialist Ear, Nose and Throat (ENT) waiting lists

A telehealth-facilitated randomised-controlled trial utilising a health promotion intervention to resolve otitis media with effusion for children won specialist Ear, Nose and Throat (ENT) waiting lists

Aboriginal Advisory Committee - Kids Easy Breathing Study

We are looking for Aboriginal parents who are passionate about lung health to join the Aboriginal Advisory Committee (AAC) for our Kids Easy Breathing Study (KEBS). Research shows 1 in 5 Aboriginal* bubs in hospital for bronchiolitis (a common viral chest infection) later had serious damage to their lungs. The aim of our study is to find out why Aboriginal bubbies are more likely to develop long-term lung sickness.

Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocol

We aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.

PneumoWA: A case-control study of the role of viral and bacterial pathogens in causing pneumonia among Western Australian children

Christopher Elke Jennifer Peter Tom Blyth Seppanen Kent Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD RN MBBS MRCP(UK) FRACP BMBS DTMH

Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial

Children in Papua New Guinea (PNG) are at high risk of pneumococcal infections. We investigated pneumococcal carriage rates, serotype distribution, and antimicrobial susceptibility in PNG children after vaccination with 10-valent or 13-valent pneumococcal conjugate vaccines (PCV10; PCV13).

Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells

Children typically experience more mild symptoms of Coronavirus Disease 2019 (COVID-19) when compared to adults. There is a strong body of evidence that children are also less susceptible to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection with the ancestral viral isolate.